Ascletis Pharma, Inc. (1672) Stock Statistics & Valuation Metrics

Ascletis Pharma, Inc. has a market cap or net worth of HK$17.93B. The enterprise value is HK$14.10B.

Ascletis Pharma, Inc. has 1,068,214,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ascletis Pharma, Inc.’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -24.22%.

The current PE Ratio of Ascletis Pharma, Inc. is ―. Ascletis Pharma, Inc.’s PEG ratio is -1.42.

In the last 12 months, Ascletis Pharma, Inc. had revenue of 1.98M and earned -350.57M in profits. Earnings per share was -0.36.

In the last 12 months, operating cash flow was -379.12M and capital expenditures -573.60K, giving a free cash flow of -379.69M billion.

Ascletis Pharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Ascletis Pharma, Inc. upcoming earnings date is Aug 24, 2026, TBA (Confirmed).

Ascletis Pharma, Inc. as a current ratio of 15.05, with Debt / Equity ratio of 0.27%

In the past 12 months, Ascletis Pharma, Inc. has paid -492.90K in taxes.

Ascletis Pharma, Inc. EV to EBITDA ratio is -18.74, with an EV/FCF ratio of -25.72.

Ascletis Pharma, Inc. has HK$1.90B in cash and marketable securities with HK$5.16M in debt, giving a net cash position of HK$1.90B billion.

Gross margin is -373.74%, with operating margin of -23853.96%, and net profit margin of -17745.57%.

The average price target for Ascletis Pharma, Inc. is HK$20.17, which is 11.43% higher than the current price. The consensus rating is Moderate Buy